Cicada covid variant: The : A New Challenge in the Pandemic Fight
The emergence of the cicada covid variant, officially known as BA.3.2, has significant implications for public health as it spreads across the United States. Detected in at least 25 states as of February 2026, this heavily mutated variant raises concerns about its ability to evade immunity from vaccines and previous infections.
First identified in South Africa in November 2024, BA.3.2 has since made its way to at least 23 countries. With 70 to 75 mutations in its spike protein, experts warn that this variant may reduce the effectiveness of current COVID-19 vaccines. Andrew Pekosz, Ph.D., noted, “It has a lot of mutations that may cause it to look different to your immune system.”
Despite these mutations, health officials, including Dr. Adolfo García-Sastre, emphasize that there is currently no evidence indicating that BA.3.2 causes more severe disease or hospitalizations compared to earlier strains. This variant was first detected in the U.S. in June 2025 in a traveler returning from the Netherlands.
The World Health Organization has classified BA.3.2 as a ‘variant under monitoring’ since December 2025, reflecting its potential impact on global health. As of early 2026, it accounts for approximately 30% of cases in Denmark, Germany, and the Netherlands, showcasing its rapid spread.
Symptoms associated with BA.3.2 include cough, fever, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues. While vaccines are expected to continue providing protection against severe disease, their effectiveness against infection may be diminished.
Current data indicates that about 3.7% of sewage samples nationwide show the presence of BA.3.2, highlighting its prevalence. Vaccination remains a crucial tool in limiting cases, as Pekosz asserts, “Vaccination is still going to help limit cases.”
However, the exact reasons for the resurgence of BA.3.2 are unclear, and the long-term impact on public health remains uncertain. Details remain unconfirmed.
